Introduction. Kidney cancer remains an urgent problem in modern oncology. More than 200 thousand new cases of kidney cancer are diagnosed globally every year, with about 100 thousand patients dying. 15–17% of patients are diagnosed with stage IV kidney cancer. Arterial tumour embolization and nephrectomy are used as a palliative treatment.Aim. To evaluate the results of renal artery embolization in combined treatment of stage IV kidney cancer.Material and methods. The treatment results of 22 patients with stage IV kidney cancer are presented: 6 patients had metastases in the skeletal bones; 15 — metastases in the lungs; 1 — bilateral kidney damage. At the first stage, all patients underwent renal artery embolization. Subsequently, 6 patients received bisphosphonates and radiation therapy for metastases in the skeletal bones, 15 patients underwent operation followed by a targeted therapy with Sunitinib and Sorafenib), 1 patient with bilateral kidney damage underwent operation followed by a 2-year targeted therapy with Sorafenib.Results and discussion. Renal artery embolization was performed successfully without technical difficulties in all the patients. After embolization, hemostasis was achieved in all patients with hematuria (n = 14). Postembolization syndrome was noted in 13 patients with total renal artery embolization. 6 patients with metastases in the skeletal bones lived for 16.4 ± 2.1 months, the survival time of 15 patients who received renal artery embolization, nephrectomy and targeted therapy was 41.7 ± 15.3 months. Only one patient (bilateral kidney damage) has been under dynamic observation for the period of 10 years.Conclusion. Renal artery embolization is an effective and minimally invasive technical procedure that should be used in the combined treatment of patients with kidney cancer. The combined use of renal artery embolization and subsequent targeted therapy for kidney cancer provide new opportunities for stage IV combined treatment.

renal cell carcinoma morbidity grows in most of countries. all over the world 200,000 new cases are diagnosed every year, and approximately 102,000 patients die of this disease, with an incidence of nearly nine cases per 100,000 inhabitants per year. that's why, renal cell carcinoma is a challenging field in the current oncology research. among urologic tumors, renal cell carcinoma ranks third in terms of incidence after prostate carcinoma and transitional cell carcinoma of the bladder. renal cell carcinoma accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney.Bilateral renal cell carcinoma (BrCC) is a rare disease with poor prognosis which accounts for 2-6% of all cases of renal cell carcinoma. only a few case reports and series with a small number of patients with bilateral renal cell carcinoma can be found in the literature.We present an interesting clinical case of bilateral renal cell carcinoma with a total survival rate of more than 10 years.

No abstract